Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: J Allergy Clin Immunol. 2014 Aug 28;135(3):701–709.e5. doi: 10.1016/j.jaci.2014.06.038

Table V.

Twenty-four week change in asthma symptoms, lung function, and sinus symptoms in adults (ages 18 and older) treated with mometasone versus placebo.

N Change from randomization
(SE)
Difference in change from randomization
(95% CI)
P-value
Mometasone Placebo Mometasone - Placebo
Asthma Symptom Utility Index 193 0.09 (0.01) 0.03 (0.02) 0.06 (0.01 ,0.11) < 0.01
Marks asthma quality of life questionnaire 192 -5.26 (1.11) -5.48 (1.06) 0.22 (-2.82 ,3.26) 0.89
Lung function
Pre-bronchodilator FEV1 (% predicted) 193 -1.40 (1.07) 0.51 (0.97) -1.91 (-4.76 ,0.94) 0.18
Pre-bronchodilator FVC (% predicted) 193 -1.27 (0.95) 0.06 (0.85) -1.33 (-3.85 ,1.19) 0.30
FEV1/FVC 193 -0.001 (0.004) 0.004 (0.004) -0.005 (-0.017 ,0.008) 0.43
FeNO (ppb)* 183 -0.08 (1.98) -0.02 (2.96) -0.06 (-7.08, 6.96) 0.99
Sinus symptoms
Sinus Symptom Score 194 -9.46 (1.18) -5.64 (1.24) -3.82 (-7.19 ,-0.45) 0.03
SN-22 193 -11.2 (1.86) -6.37 (1.75) -4.83 (-9.86 ,0.21) 0.06
*

FeNO was measured at baseline and at 24 weeks.

N = number of participants evaluable at 24 weeks; CI = confidence interval.

HHS Vulnerability Disclosure